These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31079056)

  • 41. Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis.
    Kapoor KG; Wagner AL
    Ophthalmic Res; 2016; 56(1):17-22. PubMed ID: 26982318
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive factors of selective mineralocorticoid receptor antagonist treatment in chronic central serous chorioretinopathy.
    Gergely R; Kovács I; Récsán Z; Sándor GL; Czakó C; Nagy ZZ; Ecsedy M
    Sci Rep; 2020 Oct; 10(1):16621. PubMed ID: 33024222
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Central serous chorioretinopathy induced by drugs metabolized by cytochrome P450 3A4.
    Morawski K; Klonowska A; Kubicka-Trzaska A; Woron J; Romanowska-Dixon B
    J Physiol Pharmacol; 2020 Apr; 71(2):. PubMed ID: 32776913
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy.
    Rabiolo A; Zucchiatti I; Marchese A; Baldin G; Sacconi R; Montorio D; Cicinelli MV; Querques L; Bandello F; Querques G;
    Eye (Lond); 2018 Jan; 32(1):55-66. PubMed ID: 29265111
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of eplerenone on choroidal blood flow changes during isometric exercise in patients with chronic central serous chorioretinopathy.
    Gallice M; Daruich A; Matet A; Mouvet V; Dirani A; Evequoz G; Geiser M; Behar Cohen F; Chiquet C
    Acta Ophthalmol; 2021 Dec; 99(8):e1375-e1381. PubMed ID: 33650207
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Eplerenone in patients with chronic recurring central serous chorioretinopathy.
    Leisser C; Hirnschall N; Hackl C; Plasenzotti P; Findl O
    Eur J Ophthalmol; 2016 Aug; 26(5):479-84. PubMed ID: 26692062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
    Zhao M; Célérier I; Bousquet E; Jeanny JC; Jonet L; Savoldelli M; Offret O; Curan A; Farman N; Jaisser F; Behar-Cohen F
    J Clin Invest; 2012 Jul; 122(7):2672-9. PubMed ID: 22684104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. One year outcome and predictors of treatment outcome in central serous chorioretinopathy: Multimodal imaging based analysis.
    Arora S; Maltsev DS; Singh Randhir S; Sahoo NK; Jhingan M; Parmeshwarappa D; Arora T; Kulikov A; Iovino C; Zur D; Fainberg G; Ibrahim MN; Tatti F; Gujar R; Venkatesh R; Reddy N; Snehith R; Peiretti E; Lupidi M; Chhablani J
    Eur J Ophthalmol; 2022 Jul; 32(4):2319-2327. PubMed ID: 34747194
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy.
    Shulman S; Goldenberg D; Schwartz R; Habot-Wilner Z; Barak A; Ehrlich N; Loewenstein A; Goldstein M
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):15-22. PubMed ID: 25794988
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Short-term eplerenone for treatment of chronic central serous chorioretinopathy; a prospective study.
    Moein HR; Bierman LW; Novais EA; Moreira-Neto C; Baumal CR; Rogers A; Duker JS; Witkin AJ
    Int J Retina Vitreous; 2019; 5():39. PubMed ID: 31516734
    [TBL] [Abstract][Full Text] [Related]  

  • 51. One-year outcome of cystoid macular degeneration in central serous chorioretinopathy.
    Kumar Sahoo N; Lupidi M; Goud A; Gangakhedkar S; Cardillo Piccolino F; Chhablani J
    Eur J Ophthalmol; 2022 Jul; 32(4):2347-2354. PubMed ID: 34615406
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.
    Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB
    Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599
    [No Abstract]   [Full Text] [Related]  

  • 53. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
    Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
    Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
    van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapy Rationale for Mineralocorticoid-Receptor Antagonists, Acetazolamide and a Switch of Therapy in Nonresponders in Central Serous Chorioretinopathy.
    Rübsam A; Thieme CE; Schlomberg J; Winterhalter S; Müller B; Joussen AM; Stübiger N
    J Ocul Pharmacol Ther; 2017 Apr; 33(3):141-148. PubMed ID: 28277988
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy.
    Sanhueza A; González R
    Medwave; 2020 Sep; 20(8):e8036. PubMed ID: 33017387
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Infographic: Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months: the VICI study.
    Yusuf IH; Henein C; Sivaprasad S
    Eye (Lond); 2024 Aug; 38(Suppl 2):33-34. PubMed ID: 37085716
    [No Abstract]   [Full Text] [Related]  

  • 58. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine-based delivery applications and future trends.
    Abdelhakeem E; El-Nabarawi M; Shamma R
    Br J Clin Pharmacol; 2022 Jun; 88(6):2665-2672. PubMed ID: 34983084
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Short-term comparison between navigated subthreshold microsecond pulse laser and oral eplerenone for chronic central serous chorioretinopathy.
    Toto L; D'Aloisio R; De Nicola C; Evangelista F; Ruggeri ML; Cerino L; Simonelli MB; Aharrh-Gnama A; Di Nicola M; Porreca A; Mastropasqua R
    Sci Rep; 2022 Mar; 12(1):4727. PubMed ID: 35304566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.